{"id":5227,"date":"2019-06-14T14:44:38","date_gmt":"2019-06-14T12:44:38","guid":{"rendered":"http:\/\/www.seventure.fr\/wp-content\/uploads\/2019\/06\/190528-domain-therapeutics-seventure-en.pdf"},"modified":"2019-06-14T14:44:38","modified_gmt":"2019-06-14T12:44:38","slug":"190528-domain-therapeutics-seventure-en-2","status":"inherit","type":"attachment","link":"https:\/\/www.seventure.fr\/en\/european-venture-capital-firm-seventure-partners-renews-its-support-to-domain-therapeutics-and-invests-e3-5m-3-9m-to-prepare-the-next-growth-phase\/190528-domain-therapeutics-seventure-en-2\/","title":{"rendered":"190528-domain-therapeutics-seventure-en"},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false},"class_list":["post-5227","attachment","type-attachment","status-inherit","hentry"],"acf":[],"yoast_head":"\n